Organization · Venture Capital
KHAN Technology Transfer Fund I
KHAN Technology Transfer Fund I is an early-stage life sciences venture fund based in Dortmund, Germany, focusing on first-in-class therapies and drug discovery projects sourced from academic institutions. The fund aims to bridge the gap between academia and industry by supporting innovative drug development partnerships.
Overview
What KHAN Technology Transfer Fund I does
What KHAN Technology Transfer Fund I is
KHAN Technology Transfer Fund I is an early-stage life sciences venture fund based in Dortmund, Germany, focusing on first-in-class therapies and drug discovery projects sourced from academic institutions. The fund aims to bridge the gap between academia and industry by supporting innovative drug development partnerships.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find KHAN Technology Transfer Fund I elsewhere
Open the official website or a supported primary organization account.
Capability profile
KHAN Technology Transfer Fund I as a funder
Investment thesis
KHAN Technology Transfer Fund I aims to commercialize high-potential academic drug-discovery assets that are too early for traditional venture capital. The fund focuses on innovative therapeutic opportunities with high unmet medical needs, primarily sourced from leading European academic institutions.
Focus narrative
The fund invests in early-stage life sciences projects, specifically targeting first-in-class therapeutics. KHAN emphasizes innovative technology transfer in drug discovery and collaborates closely with academic institutions, including the Max Planck Society, to support the development of drug assets. The fund provides flexible funding and support to structure projects and build companies, allowing for investments without requiring fully validated assets or complete teams at the outset.
Value beyond capital
KHAN Technology Transfer Fund I adds value to its portfolio companies by providing access to professional drug-discovery resources through its partnership with Lead Discovery Center. The fund supports the development of projects from early concepts to stages where they can attract further investment or strategic partnerships, facilitating the transition from academia to industry.
Terms and economics
- Typical check
- $500,000–$7,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 10
Portfolio context
KHAN Technology Transfer Fund I has funded over 50 scientific assets and more than 10 start-ups. Notable portfolio companies include Nodus Oncology, which develops first- and best-in-class molecules against DNA damage response targets; KyDo Therapeutics; CasInvent Pharma, focused on CRISPR therapeutics; KinSea Therapeutics, specializing in kinase inhibitors; Origami Therapeutics, involved in CNS drug discovery; and EvlaBio, which targets protein degradation.
Common questions
What to know about KHAN Technology Transfer Fund I
Upseed classifies KHAN Technology Transfer Fund I under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.